New hope for advanced liver cancer: particle beam plus immunotherapy trial launches
NCT ID NCT06828380
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II study tests whether adding particle beam radiation therapy to standard immunotherapy can help people with advanced liver cancer that has spread into major blood vessels. About 128 adults with unresectable or metastatic hepatocellular carcinoma and vascular invasion will be randomly assigned to receive immunotherapy alone or with particle beam radiation. Researchers will track how long the cancer stays under control and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
immunotherapy and particle beam radiation therapy
What this could lead to
If successful, this could show that adding particle beam radiation to immunotherapy helps control advanced liver cancer with blood vessel invasion better than immunotherapy alone.
What could go wrong
This is a phase II trial with only 128 participants, so results are preliminary. The combination may not improve survival and could increase side effects from radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center
RECRUITINGGoyang, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Samsung Medical Center, Seoul
RECRUITINGSeoul, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••